

## **Serina Therapeutics' CEO Will Lead Session on Biorelated Polymers at the 12<sup>th</sup> International Symposium of the American Chemical Society**

Huntsville, AL, March 17th, 2014

Serina Therapeutics, Inc., a pharmaceutical research and development company that has developed a proprietary, patented polymer technology for drug development, announced today that Dr. Randall Moreadith, President and CEO, will lead the session on polymer chemistry at the 12<sup>th</sup> International Symposium on Biorelated Polymers to be held in Dallas, TX on March 18<sup>th</sup>, 2014.

“The International Symposium on Biorelated Polymers will bring together experts in polymer chemistry from all over the world,” stated Dr. Moreadith. “It is a privilege to be selected as a panelist and to lead the session on next generation polymer chemistry. I look forward to updating the attendees at this meeting of our progress in developing POZ therapeutics.”

Serina Therapeutics' polymer technology, abbreviated POZ, represents a new polymer drug delivery platform. SER-214 is Serina's most advanced polymer conjugate, with plans to enter a Phase I trial in Parkinson's disease patients later this year. It is a once-per-week injectable that can be delivered in a standard insulin syringe. A single weekly injection of SER-214 has been shown to provide steady-state levels of release of rotigotine over a seven day period in monkeys, thus providing continuous dopaminergic stimulation (CDS) in experimental animals. CDS has been a long-sought clinical strategy to ameliorate the sometimes disabling consequences of oral treatment with levodopa formulations that have very short half-lives. Currently available dopaminergic drugs such as levodopa and dopamine receptor agonists impart considerable improvement in Parkinson's disease motor symptoms, but often lead to significant motor complications including “wearing-off” and dyskinesia. Such complications are believed to stem from the pulsatile nature of dopaminergic stimulation with these agents. Continuous dopaminergic drug delivery using POZ polymer conjugation may improve motor symptoms, while avoiding development of side effects.

Serina's pipeline programs now encompass applications in cancer and inflammatory diseases, and the company has established partnerships with AstraZeneca and the Scripps Research Institute.

### **About Serina**

Serina Therapeutics is a privately held pharmaceutical company located at the Hudson-Alpha Institute for Biotechnology in Huntsville, AL. The company was founded in 2007 to develop novel polymer therapeutics based on its proprietary polyoxazoline (POZ) technology platforms. The founders and managers of Serina were formerly the key principals of Shearwater Polymers, a company that enabled nine approved polyethylene glycol (PEG) products for various pharmaceutical partners – with combined 2013 annual sales of ~ \$ 7.5 billion USD. Besides developing its own pipeline of pharmaceutical products for Parkinson's disease and cancer, Serina is also partnering its technology with pharmaceutical companies to develop high value products addressing unmet clinical needs.

For more information on Serina Therapeutics, and to inquire about partnering opportunities, please visit <http://www.serinatherapeutics.com>